STARD4 and metabolic dysfunction-associated steatohepatitis: In the context of NASH, GPR35 reduces steatohepatitis severity by inducing STARD4 expression and promoting cholesterol conversion into BAs, thereby attenuating lipotoxicity (77) (Table 4).